Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Eberhardt

Showing results (151-160 of 153) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 153 results.
Physical Review Letters|April 28, 2009
Core-hole screening as a probe for a metal-to-nonmetal transition in lead clustersV Senz, T Fischer, P Oelssner, et al.
Physical Review Letters|September 21, 2011
Large tunable Rashba spin splitting of a two-dimensional electron gas in Bi2Se3P D C King, R C Hatch, M Bianchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
Pageof 16

Showing results (151-160 of 153) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 153 results.
Physical Review Letters|April 28, 2009
Core-hole screening as a probe for a metal-to-nonmetal transition in lead clustersV Senz, T Fischer, P Oelssner, et al.
Physical Review Letters|September 21, 2011
Large tunable Rashba spin splitting of a two-dimensional electron gas in Bi2Se3P D C King, R C Hatch, M Bianchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
Pageof 16